A phase I double-blind, placebo controlled (part B only), randomised trial to evaluate the safety, tolerability and pharmacokinetics of single dose in fed state, and repeated doses of DNDI-6899 in healthy participants.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DNDi 6899 (Primary)
Indications Visceral leishmaniasis
Focus Adverse reactions
Sponsors Drugs for Neglected Diseases Initiative Foundation

Most Recent Events

30 Sep 2024 New trial record
23 Sep 2024 Recruitment completion is expected on 31 Jan 2025, according to ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight